Published in Carcinogenesis on January 04, 2012
Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells. Oncoimmunology (2013) 1.47
Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol (2015) 0.96
Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood. Genome Biol (2014) 0.85
LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res (2013) 0.84
Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J Exp Med (2016) 0.78
Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. Vaccines (Basel) (2015) 0.77
Intralesional therapy for advanced melanoma: promise and limitation. Curr Opin Oncol (2015) 0.77
A novel preclinical murine model of immune-mediated metastatic dormancy. Oncoimmunology (2014) 0.75
Epigenetic modification and preliminary investigation of the mechanism of the immune evasion of HL-60 cells. Mol Med Rep (2015) 0.75
RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma. BMC Cancer (2017) 0.75
Immunoplasticity in cutaneous melanoma: beyond pure morphology. Virchows Arch (2017) 0.75
MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol (2003) 1.87
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol (2002) 1.39
The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother (2004) 1.31
Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer (2003) 1.28
MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol (2007) 1.24
Analysis of HLA-E expression in human tumors. Immunogenetics (2003) 1.23
Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol (2007) 1.22
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer (2011) 1.19
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother (2012) 1.15
Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother (2004) 1.15
High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol (2007) 1.08
Interleukin 12 (IL12B) and interleukin 12 receptor (IL12RB1) gene polymorphisms in rheumatoid arthritis. Hum Immunol (2005) 1.08
A new extract of the plant Calendula officinalis produces a dual in vitro effect: cytotoxic anti-tumor activity and lymphocyte activation. BMC Cancer (2006) 1.08
Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics (2008) 1.03
Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics (2010) 1.03
Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother (2002) 1.03
Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer (2008) 0.99
Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer (2003) 0.97
IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res (2008) 0.94
Association between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder cancer. Hum Immunol (2012) 0.93
Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer (2005) 0.91
Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother (2008) 0.91
Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother (2005) 0.91
MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer (2003) 0.90
HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol Immunother (2009) 0.90
Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother (2002) 0.90
The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells. J Pathol (2012) 0.90
The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol Immunother (2010) 0.90
HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother (2006) 0.89
VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population. Hum Immunol (2012) 0.88
The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer (2008) 0.88
Human leukocyte antigen-DQB1 and -DRB1 associations in patients with idiopathic sudden sensorineural hearing loss from a defined population of Northwest Spain. Acta Otolaryngol (2005) 0.87
High frequency of HLA-B44 allelic losses in human solid tumors. Hum Immunol (2003) 0.87
T lymphocytes restrain spontaneous metastases in permanent dormancy. Cancer Res (2014) 0.87
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer (2013) 0.86
Analysis of HLA-ABC locus-specific transcription in normal tissues. Immunogenetics (2010) 0.86
NK cells mediate increase of phagocytic activity but not of proinflammatory cytokine (interleukin-6 [IL-6], tumor necrosis factor alpha, and IL-12) production elicited in splenic macrophages by tilorone treatment of mice during acute systemic candidiasis. Clin Diagn Lab Immunol (2002) 0.85
Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics (2004) 0.85
Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer (2007) 0.85
Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother (2007) 0.85
Immunotherapy eradicates metastases with reversible defects in MHC class I expression. Cancer Immunol Immunother (2011) 0.85
A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population. Inflamm Bowel Dis (2005) 0.84
LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas. Immunogenetics (2006) 0.84
Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines. Jpn J Cancer Res (2002) 0.84
Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Semin Cancer Biol (2002) 0.84
Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother (2006) 0.83
Unraveling the roles of CBF1, CBF4 and dehydrin 1 genes in the response of table grapes to high CO₂ levels and low temperature. J Plant Physiol (2012) 0.83
Characterization of an antifungal and cryoprotective class I chitinase from table grape berries (Vitis vinifera cv. Cardinal). J Agric Food Chem (2009) 0.83
Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunol Immunother (2009) 0.83
A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma. Hum Immunol (2008) 0.82
Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells. Int J Cancer (2011) 0.82
Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients. Hum Immunol (2010) 0.82
Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line. Cancer Immunol Immunother (2002) 0.82
Analysis of a GT microsatellite in the promoter of the foxp3/scurfin gene in autoimmune diseases. Hum Immunol (2005) 0.82
International conference: progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain. Cancer Immunol Immunother (2007) 0.81
Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol (2009) 0.81
Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape. Cancer Immunol Immunother (2011) 0.81
Late pulmonary metastases of renal cell carcinoma immediately after post-transplantation immunosuppressive treatment: a case report. J Med Case Rep (2008) 0.81
Cancer immune escape: implications for immunotherapy, Granada, Spain, October 3-5, 2011. Cancer Immunol Immunother (2012) 0.80
Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. Cancer Immunol Immunother (2011) 0.80
Identification of the protein components of protein-bound polysaccharide (PSK) that interact with NKL cells. Cancer Immunol Immunother (2004) 0.80
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunol Immunother (2004) 0.80
TAP1 and TAP2 polymorphisms and their linkage disequilibrium with HLA-DR, -DP, and -DQ in an eastern Andalusian population. Hum Immunol (2005) 0.79
Role of glutathione in the induction of apoptosis and c-fos and c-jun mRNAs by oxidative stress in tumor cells. Cancer Lett (2004) 0.79
Association of a functional inducible nitric oxide synthase promoter variant with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol (2005) 0.79
Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response. Int J Cancer (2007) 0.79
Modification of phagocytosis and cytokine production in peritoneal and splenic murine cells by erythromycin A, azithromycin and josamycin. J Antimicrob Chemother (2004) 0.78
Inducible nitric oxide synthase polymorphism is associated with susceptibility to Henoch-Schönlein purpura in northwestern Spain. J Rheumatol (2005) 0.78
The crucial role of Φ- and K-segments in the in vitro functionality of Vitis vinifera dehydrin DHN1a. Phytochemistry (2014) 0.78
Involvement of the chaperone tapasin in HLA-B44 allelic losses in colorectal tumors. Int J Cancer (2005) 0.77